Author

Angelika Joos

Observed names: A. Joos, Joos, A.

Institution: MSD (Belgium)

Observed institutions: MSD (Belgium), MSD (Belgium)

ORCID: 0000-0001-9585-265X

Observed ORCID: 0000-0001-9585-265X

OpenAlex ID: A5055451533

Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action

2015 · Anton Hoos, James Anderson, et al. · Therapeutic Innovation & Regulatory Science · 210

PDF

Historical Data Analyses and Scientific Knowledge Suggest Complete Removal of the Abnormal Toxicity Test as a Quality Control Test

2014 · Joerg H.O. Garbe, Susanne Ausborn, et al. · Journal of Pharmaceutical Sciences · 29

PDF

Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements

2021 · Hannah Sievers, Angelika Joos, et al. · International Journal of Technology Assessment in Health Care · 23

PDF

Moving toward a paradigm shift in the regulatory requirements for pediatric medicines

2016 · William Wei Lim Chin, Angelika Joos · European Journal of Pediatrics · 20

Optimizing Pediatric Medicine Developments in the European Union Through Pragmatic Approaches

2021 · Winona Rei Bolislis, Gesine Bejeuhr, et al. · Clinical Pharmacology & Therapeutics · 11

PDF

Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?

2018 · Hans‐Georg Eichler, Nicola Bedlington, et al. · Clinical Pharmacology & Therapeutics · 10

PDF

Clinical Trial Results Summary for Laypersons: A User Testing Study

2018 · D. K. Raynor, L. Myers, et al. · Therapeutic Innovation & Regulatory Science · 10

Early Dialogue in Europe: Perspectives on Value, Challenges, and Continuing Evolution

2018 · Lina Balaisyte, Angelika Joos, et al. · International Journal of Technology Assessment in Health Care · 10

Orphan Medicines for Pediatric Use: A Focus on the European Union

2019 · Winona Rei Bolislis, Solange Corriol-Rohou, et al. · Clinical Therapeutics · 9

PDF

What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements

2023 · Nevena Miletic, Sarah Adam, et al. · Frontiers in Medicine · 5

PDF

Reliance into Action

2025 · Isabelle Colmagne Poulard, Susanne Ausborn, et al. · Therapeutic Innovation & Regulatory Science · 4

PDF

Pediatric Market Access: A Qualitative Study

2024 · Lieke Maas, Angelika Joos, et al. · Therapeutic Innovation & Regulatory Science · 3

PDF

Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development

2022 · Leon Rohde, Elias Mossialos, et al. · Journal of Global Antimicrobial Resistance · 2

PDF

Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries

2025 · E. Reith, L. Maas, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 1

PDF

Works count: 15

Citation count: 347

H-index: 9

I10-index: 8